肝癌细胞上皮-间质转化中微小RNA通路调控的研究进展

doi:10.3969/j.issn.1004-583X.2026.07.014

摘要/Abstract

摘要：

近年来,随着对肝癌细胞上皮-间质转化(epithelial-mesenchymal transition, EMT)分子机制的深入探究,微小RNA被证明可作为肝癌诊断、治疗、预后的潜在靶点,并参与肝癌相关基因表达的调控,进而在肝癌细胞的增殖、迁移、侵袭和EMT等方面发挥重要作用。本文就近年来微小RNA调控肝癌细胞EMT及在肝癌治疗中的作用机制、与长链非编码RNA和环状RNA在肝癌细胞EMT中的协同调控网络,及临床前与临床研究进展进行综述,旨在为临床提供参考。

关键词: 肝肿瘤, 微RNAs, 上皮-间质转化, 治疗靶点, 调控网络

中图分类号:

R735.7

张天娇, 宋菲, 由佳鹭, 金雨佳, 孙妍. 肝癌细胞上皮-间质转化中微小RNA通路调控的研究进展[J]. 临床荟萃, 2026, 41(7): 659-667.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.07.014

https://www.lchc.cn/CN/Y2026/V41/I7/659

图/表 3

参考文献 58

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3) : 209-249. doi: 10.3322/caac.21660.
[2]	Mittal V. Epithelial mesenchymal transition in tumor metastasis[J]. Annu Rev Pathol, 2018, 13:395-412. doi:10.1146/annurev-pathol-020117-043854. pmid: 29414248
[3]	Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 1993, 75(5):843-854.doi:10.1016/0092-8674(93)90529-y. pmid: 8252621
[4]	Peng Y, Croce CM. The role of microRNAs in human cancer[J]. Signal Transduct Target Ther, 2016, 1:15004.doi: 10.1038/sigtrans.2015.4.
[5]	Tian T, Wang M, Zhu W, et al. MiR-146a and miR-196a-2 polymorphisms are associated with hepatitis virus-related hepatocellular cancer risk: A meta-analysis[J]. Aging (Albany NY), 2017, 9(2):381-392. doi: 10.18632/aging.101160.
[6]	Szabo G, Bala S. MicroRNAs in liver disease[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(9):542-552. doi:10.1038/nrgastro.2013.87. pmid: 23689081
[7]	Trelstad RL, Hay ED, Revel JD. Cell contact during early morphogenesis in the chick embryo[J]. Dev Biol, 1967, 16(1):78-106. doi:10.1016/0012-1606(67)90018-8. pmid: 6035571
[8]	Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition[J]. J Clin Invest, 2009, 119(6):1420-1428. doi:10.1172/JCI39104. pmid: 19487818
[9]	Debnath P, Huirem RS, Dutta P, et al. Epithelial-mesenchymal transition and its transcription factors[J]. Biosci Rep, 2022, 42(1):BSR20211754. doi:10.1042/BSR20211754.
[10]	Song G, Yu X, Shi H, et al. MiRNAs in HCC, pathogenesis, and targets[J]. Hepatology, 2024:10.1097/HEP.0000000000001177. doi: 10.1097/HEP.0000000000001177.
[11]	Gregory PA, Bracken CP, Bert AG, et al. MicroRNAs as regulators of epithelial-mesenchymal transition[J]. Cell Cycle, 2008, 7(20):3112-3118. doi:10.4161/cc.7.20.6851. pmid: 18927505
[12]	Cavallari I, Ciccarese F, Sharova E, et al. The miR-200 family of microRNAs: Fine tuners of epithelial-mesenchymal transition and circulating cancer biomarkers[J]. Cancers (Basel), 2021, 13(23):5874. doi:10.3390/cancers13235874.
[13]	杨西胜. MiR-200a/ZEB2调控肝癌干性样细胞恶性表型转化的机制研究[D]. 西安: 第四军医大学临床医学外科学, 2015.
[14]	Chen S, Zhang J, Chen Q, et al. MicroRNA-200a and microRNA-141 have a synergetic effect on the suppression of epithelial-mesenchymal transition in liver cancer by targeting STAT4[J]. Oncol Lett, 2021, 21(2):137. doi:10.3892/ol.2020.12398. pmid: 33552256
[15]	Hung CS, Liu HH, Liu JJ, et al. MicroRNA-200a and -200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers[J]. Ann Surg Oncol, 2013, 20 Suppl 3:S360-S368. doi:10.1245/s10434-012-2482-4.
[16]	贾鹂, 杨志宏, 马俊利. 贞芪扶正颗粒通过 miR-200c/ZEB 通路抑制肝癌模型大鼠血管形成[J]. 中国比较医学杂志, 2020, 30 (6) : 31-38. doi: 10.3969/j.issn.1671-7856.2020.06.005.
[17]	Wang Z, Wang W, Zhou L, et al. MiR-34a targets SNAI1 and is essential for 5-hydroxytryptamine induced epithelial mesenchymal transition in liver cancer[J]. Minerva Gastroenterol (Torino), 2022, 68(3):363-365. doi:10.23736/S2724-5985.21.03041-2.
[18]	Li DP, Fan J, Wu YJ, et al. MiR-155 up-regulated by TGF-βpromotes epithelial-mesenchymal transition, invasion and metastasis of human hepatocellular carcinoma cells in vitro[J]. Am J Transl Res, 2017, 9(6):2956-2965.
[19]	Kong X, Liu F, Gao J. MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SGK3/β-catenin signaling pathways[J]. Oncotarget, 2016, 7(40):66051-66060. doi:10.18632/oncotarget.11800. pmid: 27602769
[20]	Bao L, Yan Y, Xu C, et al. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways[J]. Cancer Lett, 2013, 337(2):226-236.doi:10.1016/j.canlet.2013.05.007. pmid: 23684551
[21]	苏秋铭. CD97通过调控PI3K/AKT/mTOR通路促进肝细胞癌的增殖、侵袭和转移的机制研究[D]. 昆明: 昆明医科大学, 2023.doi:10.27202/d.cnki.gkmyc.2023.000044.
[22]	Wang LJ, He CC, Sui X, et al. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN[J]. Oncotarget, 2015, 6(8): 5932-5946. doi:10.18632/oncotarget.3465.
[23]	相乐阳, 杨定华. miR-203的转录调控及在肿瘤中的研究进展[J]. 广东医学, 2017, 38(S1):308-312. doi:10.13820/j.cnki.gdyx.2017.s1.118.
[24]	张国柄, 徐江海, 王东风. miR-203a-3p通过SLUG调控上皮间质化抑制肝癌细胞的迁移及侵袭[J]. 肝脏, 2021, 26(12):1339-1343. doi:10.14000/j.cnki.issn.1008-1704.2021.12.013.
[25]	Zhu Y, Liu Y, Xiao B, et al. The circular RNA PVT1/miR-203/HOXD3 pathway promotes the progression of human hepatocellular carcinoma[J]. Biol Open, 2019, 8(9):bio043687. doi:10.1242/bio.043687.
[26]	蔡岳, 张赤志, 王晓东, 等. 皂荚提取物对肝癌大鼠微小RNA- 21 及磷酸酶及张力蛋白同源基因的影响[J]. 中华肝脏病杂志, 2018, 26(2) : 142-144. doi:10.3760/cma.j.issn.1007-3418.2018.02.013.
[27]	Zhao N, Sun H, Sun B, et al. miR-27a-3p suppresses tumor metastasis and VM by down- regulating VE-cadherin expression and inhibiting EMT: An essential role for twist-1 in HCC[J]. Sci Rep, 2016, 6:23091. doi:10.1038/srep23091. pmid: 26980408
[28]	邬昊. miR-29c-3p通过DNMT3B参与Hippo信号通路调控肝癌恶性生物学行为的机制研究[D]. 重庆: 重庆医科大学, 2020.doi:10.27674/d.cnki.gcyku.2020.000144.
[29]	Wang X, Liu S, Cao L, et al. miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma[J]. Oncotarget, 2017, 8:86592-86603. doi:10.18632/oncotarget.21246. pmid: 29156819
[30]	肖志华. XPD通过miR-29a-3p-Mdm2/PDGF-B轴抑制HCC细胞增殖和迁移的机制研究[D]. 南昌: 南昌大学, 2021.doi:10.27232/d.cnki.gnchu.2021.003939.
[31]	Winkle M, El-Daly SM, Fabbri M, et al. Noncoding RNA therapeutics - challenges and potential solutions[J]. Nat Rev Drug Discov, 2021, 20(8):629-651. doi: 10.1038/s41573-021-00219-z. pmid: 34145432
[32]	Rupaimoole R, Slack FJ. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3):203-222. doi: 10.1038/nrd.2016.246. pmid: 28209991
[33]	Thomson DW, Dinger ME. Endogenous microRNA sponges: Evidence and controversy[J]. Nat Rev Genet, 2016, 17(5):272-283. doi:10.1038/nrg.2016.20. pmid: 27040487
[34]	Ma WK, Voss DM, Scharner J, et al. ASO-based PKM splice-switching therapy inhibits hepatocellular carcinoma growth[J]. Cancer Res, 2022, 82(5):900-915. doi: 10.1158/0008-5472.CAN-20-0948.
[35]	Li D, Zhang J, Li J. Role of miRNA sponges in hepatocellular carcinoma[J]. Clin Chim Acta, 2020, 500:10-19. doi: 10.1016/j.cca.2019.09.013. pmid: 31604064
[36]	Wang P, Zhou Y, Richards AM. Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry[J]. Theranostics, 2021, 11(18):8771-8796. doi: 10.7150/thno.62642. pmid: 34522211
[37]	Forterre A, Komuro H, Aminova S, et al. A comprehensive review of cancer microRNA therapeutic delivery strategies[J]. Cancers (Basel), 2020, 12(7):1852. doi: 10.3390/cancers12071852.
[38]	Seyhan AA. Trials and tribulations of microRNA therapeutics[J]. Int J Mol Sci, 2024, 25(3):1469. doi: 10.3390/ijms25031469.
[39]	Kumar MA, Baba SK, Sadida HQ, et al. Extracellular vesicles as tools and targets in therapy for diseases[J]. Signal Transduct Target Ther, 2024, 9(1):27. doi: 10.1038/s41392-024-01735-1.
[40]	Liang G, Kan S, Zhu Y, et al. Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells[J]. Int J Nanomedicine, 2018, 13:585-599. doi: 10.2147/IJN.S154458.
[41]	Kong M, Li W, Li H, et al. m6A methylation-mediated lncRNA RNF144A-AS1 promotes hepatocellular carcinoma progression through the miR-1301-3p/RNF38 pathway[J]. Biol Direct, 2025, 20(1):91. doi: 10.1186/s13062-025-00681-4.
[42]	Xu B, Li C, Yang B, et al. LncRNA SNHG20 silencing inhibits hepatocellular carcinoma progression by sponging miR-5095 from MBD1[J]. Am J Transl Res, 2023, 15(6):4314-4331. pmid: 37434830
[43]	Liu P, Zhong Q, Song Y, et al. Long noncoding RNA linc01612 represses hepatocellular carcinoma progression by regulating miR-494/ATF3/p53 axis and promoting ubiquitination of YBX1[J]. Int J Biol Sci, 2022, 18(7):2932-2948. doi: 10.7150/ijbs.69514. pmid: 35541917
[44]	Chen S, Cao X, Zhang J, et al. circVAMP3 drives CAPRIN1 phase separation and inhibits hepatocellular carcinoma by suppressing c-Myc translation[J]. Adv Sci (Weinh), 2022, 9(8):e2103817. doi: 10.1002/advs.202103817.
[45]	Liu L, Gu M, Ma J, et al. CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma[J]. Mol Cancer, 2022, 21(1):149.doi: 10.1186/s12943-022-01619-4. pmid: 35858900
[46]	Fei D, Wang F, Wang Y, et al. Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway[J]. Mol Cancer, 2024, 23(1):159. doi: 10.1186/s12943-024-02074-z. pmid: 39107843
[47]	Olarewaju O, Hu Y, Tsay HC, et al. MicroRNA miR-20a-5p targets CYCS to inhibit apoptosis in hepatocellular carcinoma[J]. Cell Death Dis, 2024, 15(6):456. doi: 10.1038/s41419-024-06841-0. pmid: 38937450
[48]	Bocchetti M, Cossu AM, Porru M, et al. MiR-423-5p is a metabolic and growth tuner in hepatocellular carcinoma via MALAT-1 and mitochondrial interaction[J]. J Exp Clin Cancer Res, 2025, 44(1):270. doi: 10.1186/s13046-025-03524-2.
[49]	Tonon F, Grassi C, Tierno D, et al. Non-coding RNAs as potential diagnostic/prognostic markers for hepatocellular carcinoma[J]. Int J Mol Sci, 2024, 25(22):12235. doi: 10.3390/ijms252212235.
[50]	Molina-Pelayo FA, Zarate-Lopez D, García-Carrillo R, et al. MiRNAs-set of plasmatic extracellular vesicles as novel biomarkers for hepatocellular carcinoma diagnosis across tumor stage and etiologies[J]. Int J Mol Sci, 2025, 26(6):2563. doi: 10.3390/ijms26062563.
[51]	Chen R, Hu X, Huang Y, et al. Regulated cell death in lenvatinib resistance of hepatocellular carcinoma: From molecular mechanisms to therapeutic strategies[J]. Int J Biol Sci, 2025, 21(5):2012-2026. doi:10.7150/ijbs.107195. pmid: 40083703
[52]	Hu Z, Zhao Y, Mang Y, et al. MiR-21-5p promotes sorafenib resistance and hepatocellular carcinoma progression by regulating SIRT7 ubiquitination through USP24[J]. Life Sci, 2023, 325:121773. doi: 10.1016/j.lfs.2023.121773.
[53]	Rong J, Liu T, Yin X, et al. Co-delivery of camptothecin and MiR-145 by lipid nanoparticles for MRI-visible targeted therapy of hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2024, 43(1):247. doi: 10.1186/s13046-024-03167-9. pmid: 39215325
[54]	Zhang W, Fu T, Guo Z, et al. Serum miR-375 levels are closely related to disease progression from HBV infection to HBV-related hepatocellular carcinoma[J]. Biomed Res Int, 2020, 2020:5819385. doi: 10.1155/2020/5819385.
[55]	Zhang YM, Wu QM, Chang LY, et al. miR-34a and miR-125a-5p inhibit proliferation and metastasis but induce apoptosis in hepatocellular carcinoma cells via repressing the MACC1-mediated PI3K/AKT/mTOR pathway[J]. Neoplasma, 2020, 67(5):1042-1053. doi: 10.4149/neo_2020_191019N1062. pmid: 32484698
[56]	Hong DS, Kang YK, Borad M, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours[J]. Br J Cancer, 2020, 122(11):1630-1637.doi: 10.1038/s41416-020-0802-1.
[57]	Wang Z, Peng Y, Zhou H, et al. MiRNA-based drugs: Challenges and delivery strategies[J]. Appl Microbiol Biotechnol, 2025, 109(1):247. doi: 10.1007/s00253-025-13620-0.
[58]	Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer[J]. Adv Drug Deliv Rev, 2022, 182:114113. doi: 10.1016/j.addr.2022.114113.

miRNA	靶点	功能	参考文献
miR-200a	ZEB1/2、STAT4	低表达的miR-200a可直接上调肿瘤转录抑制因子ZEB1/2,促进EMT	杨西胜^[13],Chen等^[14]
miR-200b	ZBE1/2	起肿瘤抑制剂的作用,通过上调E-钙黏蛋白影响肿瘤细胞的迁移	Hung等^[15]
miR-200c	ZEB1/2	负调控ZEB2促进肝癌新生血管形成,加速肝癌细胞恶化	贾鹂等^[16]
miR-34a	SNAI1	减少SNAI1和波形蛋白水平并增加E-钙黏蛋白水平,达到逆转5-HT所诱导的EMT的效果	Wang等^[17]
miR-155	FN1、SNAI1、ZEB1	上调FN1、SNAI1、ZEB1和波形蛋白的表达,并下调E-钙黏蛋白的表达,进一步促进EMT	Li等^[18]
miR-21	PTEN、hSulf-1	活化AKT/ERK信号通路,促进肝癌细胞EMT	Bao等^[20]
miR-203	HOXD3、circPVT1	致癌基因circPVT1通过碱基互补配对竞争性结合miR-203,调节其表达,达到下调HOXD3的效果,最终诱导肝癌细胞增殖,促进其迁移能力	Zhu等^[25]
miR-27a-3p	Twist1	抑制肝癌细胞EMT	Zhao等^[27]
miR-29	IGF-1R、XPD	本身能够直接导致某些肿瘤的EMT;也可通过XPD-miR-29a/p53/MDM2/PDGF-B通路,抑制肝癌细胞的增殖和迁移	邬昊^[28],肖志华^[30]

miRNA	靶点	功能	参考文献
miR-200a	ZEB1/2、STAT4	低表达的miR-200a可直接上调肿瘤转录抑制因子ZEB1/2,促进EMT	杨西胜^[13],Chen等^[14]
miR-200b	ZBE1/2	起肿瘤抑制剂的作用,通过上调E-钙黏蛋白影响肿瘤细胞的迁移	Hung等^[15]
miR-200c	ZEB1/2	负调控ZEB2促进肝癌新生血管形成,加速肝癌细胞恶化	贾鹂等^[16]
miR-34a	SNAI1	减少SNAI1和波形蛋白水平并增加E-钙黏蛋白水平,达到逆转5-HT所诱导的EMT的效果	Wang等^[17]
miR-155	FN1、SNAI1、ZEB1	上调FN1、SNAI1、ZEB1和波形蛋白的表达,并下调E-钙黏蛋白的表达,进一步促进EMT	Li等^[18]
miR-21	PTEN、hSulf-1	活化AKT/ERK信号通路,促进肝癌细胞EMT	Bao等^[20]
miR-203	HOXD3、circPVT1	致癌基因circPVT1通过碱基互补配对竞争性结合miR-203,调节其表达,达到下调HOXD3的效果,最终诱导肝癌细胞增殖,促进其迁移能力	Zhu等^[25]
miR-27a-3p	Twist1	抑制肝癌细胞EMT	Zhao等^[27]
miR-29	IGF-1R、XPD	本身能够直接导致某些肿瘤的EMT;也可通过XPD-miR-29a/p53/MDM2/PDGF-B通路,抑制肝癌细胞的增殖和迁移	邬昊^[28],肖志华^[30]

肝癌细胞上皮-间质转化中微小RNA通路调控的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 58

相关文章 15

编辑推荐

Metrics

本文评价

[1]	冯利菲, 王天慧, 吕慧. 血清AFP、AFP-L3、HSP90α对乙肝肝硬化和乙肝相关性肝癌的鉴别价值及其与HBV-DNA载量的关系[J]. 临床荟萃, 2026, 41(6): 505-510.
[2]	王天慧, 吕慧, 冯利菲, 陈亚杰. 血清FABP5、SII、VEGF水平与肝癌患者预后的关系分析[J]. 临床荟萃, 2026, 41(5): 399-405.
[3]	姜俊辰, 郭蓉娟, 张帆, 刘佳霖. MAPK信号通路在脑出血中的研究进展[J]. 临床荟萃, 2026, 41(3): 269-273.
[4]	邢路超, 苑建磊. 肝细胞癌代谢重编程研究进展[J]. 临床荟萃, 2025, 40(12): 1136-1141.
[5]	申彤彤, 匡竞, 王玮. 血清肿瘤标志物在肝细胞癌早期诊断中的应用[J]. 临床荟萃, 2024, 39(6): 563-567.
[6]	郭文惠, 雷皓月, 潘友卓, 张琦. 质膜膜泡关联蛋白的生物学功能研究进展[J]. 临床荟萃, 2023, 38(7): 647-653.
[7]	李亚, 杜涛明, 邱世香, 陈超, 钟立明. 伴有抑郁症状肝癌患者脑功能连接研究[J]. 临床荟萃, 2023, 38(6): 532-536.
[8]	李亚, 邱世香, 陈超, 钟立明. 肝癌患者抑郁相关因素及其与生活质量的关系[J]. 临床荟萃, 2022, 37(6): 539-543.
[9]	吴天娇, 常璐, 李梓浩, 徐丹, 尹昌浩, 赵维纳. 微RNA在血管性认知障碍发病机制中的研究进展[J]. 临床荟萃, 2022, 37(4): 364-368.
[10]	郭小军, 孔延亮, 刘涛, 成正祥, 张睿, 樊雷. CT引导经皮射频消融术治疗肝癌分析[J]. 临床荟萃, 2021, 36(9): 807-810.
[11]	陶嘉楠, 王学红, 张宏琳. miR-146b在恶性肿瘤中的研究进展[J]. 临床荟萃, 2021, 36(8): 765-768.
[12]	陈礼龙, 刘务朝, 司秋艳, 张建平, 程荣, 吴权. 不同剂量硫酸氢氯吡格雷对脑梗死患者血流动力学指标及血清miR-191、miR-18a水平的影响[J]. 临床荟萃, 2021, 36(7): 608-611.
[13]	谢志海, 周志聪, 桂元, 孙静锋. IGF1R反义非编码RNA在肝癌中的差异化表达[J]. 临床荟萃, 2021, 36(7): 620-622.
[14]	孙婷婷1，郭健2a，孙雯雯2b，赵燕珍1，刘丽敏1，朱斌1. 慢性丙型肝炎患者合并糖尿病对肝癌发生率影响的Meta分析[J]. 临床荟萃, 2018, 33(6): 519-524,531.
[15]	黄洁1，2，聂芳1，杨理雯2，李静1. 超声评价2型糖尿病患者并发原发性肝癌特点及相关因素分析[J]. 临床荟萃, 2017, 32(10): 873-876.